Abstract

Last year we noted that some large-scale trials of drugs in general practice seemed to have more to do with promotion than with science,¹ and in June Mike Thomas MP introduced a Private Member’s Bill to discourage trials that are largely promotional.² We therefore welcome the recent announcement by the Minister of Health that the DHSS intends to draw up a voluntary code of practice for clinical trials conducted after a drug has been marketed. Various interested bodies will be consulted, including the RCGP, the BMA and the ABPI.³ While the rules are being worked out, manufacturers planning trials and doctors asked to take part in them will no doubt consider the ethical and scientific aspects with special care.